Literature DB >> 23080487

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Cathia Soulié1, Charlotte Charpentier, Philippe Flandre, Clément Nino, Guislaine Carcelain, Anne Simon, Christine Katlama, Roland Landman, Françoise Brun-Vézinet, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin.   

Abstract

The HIV-1 coreceptor usage may play a critical role in AIDS pathogenesis and the X4-using viruses are considered to be more pathogenic than the R5-tropic viruses. These observations may influence the therapeutic decisions by asking for an earlier antiretroviral (ARV) treatment for the patients infected by the X4-tropic viruses compared with those infected by the R5-tropic viruses. The natural evolution of CD4+ cell count for 109 non-treated patients infected by the R5- or X4-tropic HIV-1 viruses with CD4+ >350 and >500 cells/mm(3) at time of diagnosis was compared until the initiation of an ARV regimen. The coreceptor usage was determined from the V3 env region sequence by Geno2Pheno (false positive rate 10%). A mixed linear regression model to analyse the CD4+ data with tropism as fixed effect in the model was used. Overall, 93 (85.3%) and 16 (14.7%) were infected by R5- and X4-tropic viruses, respectively. The median age, baseline CD4+ cell count, and viral load were 34 years (IQR: 30-42), 523 cells/mm(3) (IQR: 420-604), and 4.5 log(10)  copies/ml (IQR: 3.9-5.0), respectively. There was no statistical difference in time to progression between the patients harboring R5- or X4-tropic viruses. The same results were observed for the sub-group of patients with CD4+ cell count >500 cells/mm(3). The virus tropism has no impact on the CD4+ cell count evolution in these HIV-1 patients diagnosed with CD4+ >350 or >500 cells/mm(3) suggesting that the tropism determination at time of diagnosis does not seem to be a useful tool to predict the clinical progression.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23080487     DOI: 10.1002/jmv.23362

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

2.  Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.

Authors:  Anthony Kebira Nyamache; Anne W T Muigai; Zipporah Ng'ang'a; Samoel A Khamadi
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-21       Impact factor: 2.205

3.  A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.

Authors:  Daniele Armenia; Cathia Soulie; Domenico Di Carlo; Lavinia Fabeni; Caterina Gori; Federica Forbici; Valentina Svicher; Ada Bertoli; Loredana Sarmati; Massimo Giuliani; Alessandra Latini; Evangelo Boumis; Mauro Zaccarelli; Rita Bellagamba; Massimo Andreoni; Anne-Geneviève Marcelin; Vincent Calvez; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo-Federico Perno; Maria Mercedes Santoro
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

4.  Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.

Authors:  Antonella Castagna; Laura Monno; Stefania Carta; Laura Galli; Stefania Carrara; Valentina Fedele; Grazia Punzi; Iuri Fanti; Pietro Caramello; Alessandro Cozzi Lepri; Andrea De Luca; Francesca Ceccherini-Silberstein; Antonella d'Arminio Monforte
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.